Document Detail


Human monoclonal antibodies in cancer therapy: a review of recent developments.
MedLine Citation:
PMID:  23276961     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
In the last decade, phage-display technology for the generation of monoclonal antibodies (mAbs) has improved significantly. Several novel human mAbs directed to a wide range of targets have been generated for the treatment of common malignancies. These targets include antigens associated with apoptosis, angiogenesis and solid tumors, as well as tumor growth-related antigens, insulin-like growth factor I receptor and hepatocyte growth factor. The safety, pharmacokinetics, and pharmacodynamics of several human mAbs have been evaluated in patients with advanced solid tumors. In conclusion, significant advances in the generation and application of human mAbs in cancer therapy have been made in the last decade.
Authors:
Lin Xin; Jiaqing Cao; Hua Cheng; Fei Zeng; Xiaoyun Hu; Jianghua Shao
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review     Date:  2013-01-01
Journal Detail:
Title:  Frontiers in bioscience (Landmark edition)     Volume:  18     ISSN:  1093-4715     ISO Abbreviation:  Front Biosci (Landmark Ed)     Publication Date:  2013  
Date Detail:
Created Date:  2013-01-01     Completed Date:  2013-06-12     Revised Date:  2013-07-29    
Medline Journal Info:
Nlm Unique ID:  101612996     Medline TA:  Front Biosci (Landmark Ed)     Country:  United States    
Other Details:
Languages:  eng     Pagination:  765-72     Citation Subset:  IM    
Affiliation:
Department of General Surgery, The Second Affiliated Hospital of NanChang University, 330006 Nanchang, Jiangxi, China. xinlindoc@yeah.net
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Angiopoietin-2 / immunology
Antibodies, Monoclonal / administration & dosage,  biosynthesis,  pharmacokinetics,  therapeutic use*
Apoptosis / immunology
Cell Surface Display Techniques
Humans
Neoplasms / drug therapy*
Neovascularization, Pathologic / immunology
Receptor, IGF Type 1 / immunology
Receptor, Platelet-Derived Growth Factor alpha / immunology
Recombinant Fusion Proteins / pharmacokinetics
Chemical
Reg. No./Substance:
0/Angiopoietin-2; 0/Antibodies, Monoclonal; 0/L19mTNFalpha protein; 0/PAM-1 monoclonal antibody, human; 0/Recombinant Fusion Proteins; 0/intetumumab; 0/mapatumumab; EC 2.7.10.1/Receptor, IGF Type 1; EC 2.7.10.1/Receptor, Platelet-Derived Growth Factor alpha

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Tendon-derived stem cells as a new cell source for tendon tissue engineering.
Next Document:  Role of mast cells in gynecological neoplasms.